Search research articles
Contact Us
Filters
Showing results (51-60 of 59) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 59 results.
Antimicrobial Agents and Chemotherapy
|
December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis
Stefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.
Antiviral Therapy
|
April 6, 2013
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results
Stefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Digestive Diseases and Sciences
|
May 13, 2022
Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort
Paul J Clark, Patricia C Valery, Simone I Strasser, et al.
BMC Gastroenterology
|
July 12, 2022
Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up
Paul J Clark, Patricia C Valery, James Ward, et al.
Hepatology (Baltimore, Md.)
|
April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
Nancy Reau, Paul Y Kwo, Susan Rhee, et al.
Alimentary Pharmacology & Therapeutics
|
May 6, 2022
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels
Samuel A L Hall, Gareth S Burns, Despina Anagnostou, et al.
The Lancet. Infectious Diseases
|
February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Michael Manns, Didier Samuel, Edward J Gane, et al.
JAMA
|
May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
Fred Poordad, William Sievert, Lindsay Mollison, et al.
The Journal of Infectious Diseases
|
September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways
Samuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 59) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 59 results.
Antimicrobial Agents and Chemotherapy
|
December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis
Stefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.
Antiviral Therapy
|
April 6, 2013
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results
Stefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Digestive Diseases and Sciences
|
May 13, 2022
Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort
Paul J Clark, Patricia C Valery, Simone I Strasser, et al.
BMC Gastroenterology
|
July 12, 2022
Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up
Paul J Clark, Patricia C Valery, James Ward, et al.
Hepatology (Baltimore, Md.)
|
April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
Nancy Reau, Paul Y Kwo, Susan Rhee, et al.
Alimentary Pharmacology & Therapeutics
|
May 6, 2022
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels
Samuel A L Hall, Gareth S Burns, Despina Anagnostou, et al.
The Lancet. Infectious Diseases
|
February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Michael Manns, Didier Samuel, Edward J Gane, et al.
JAMA
|
May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
Fred Poordad, William Sievert, Lindsay Mollison, et al.
The Journal of Infectious Diseases
|
September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways
Samuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
Page
of 6